Related Experiment Videos

RE: Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial

Miguel Martin¹, John Boyer², Mary Stuart³

¹Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

Journal of the National Cancer Institute

|April 5, 2017

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Moving Forward Together: A Protocol to Co-Adapt and Scale a Videoconference-Delivered Physical Activity Intervention for Children and Adolescents Diagnosed With Cancer or Blood Disorders in British Columbia, Ontario, and the Maritime Provinces.

JMIR research protocols·2026

Cardio-Oncology Nursing Education (CONE): an innovative educational program for nurses caring for patients with cancer and concurrent cardiovascular disease.

Cardio-oncology (London, England)·2026

CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.

Future oncology (London, England)·2025

Nursing knowledge in cardio-oncology: results of an international learning needs-assessment survey.

Cardio-oncology (London, England)·2025

A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer.

Future oncology (London, England)·2022

Robotic surgery: financial impact of surgical trays optimization in bariatric and thoracic surgery.

Journal of robotic surgery·2022

See all related articles